This site is intended for US Healthcare Professionals only.
more than a skin disease
Despite the QoL burden associated with PsO, many patients remain untreated.1,2 Based on patient-reported treatment patterns from an international survey, 56% of patients who described extensive disease with psoriasis lesions involving body surface area corresponding to more than 10 palms reported being treated with an oral and/or biologic systemic therapy, while 58% of patients with involvement corresponding to 4-10 palms reported being treated with an oral and/or biologic.2 Furthermore, 12% of the patients who reported >10 palms BSA involvement and 16% who reported 4-10 palms BSA involvement reported receiving no prescription or phototherapy treatment at all, highlighting unmet needs in the management of PsO.2
Patients have reported dissatisfaction in multiple areas, including safety, ease of use, efficacy, and burden of treatment.2–4 A challenge for dermatologists is identifying which drug to prescribe for each patient, a decision that may commonly be based on the patient’s preference and medical history.1,5 However, this can result in patients cycling through several therapies before landing on one that works best for them.1,6 This extended period of cycling through different options may contribute to disease progression and poor outcomes.6
Surveys suggest there are unmet needs in psoriasis 
aModerate psoriasis = 4-10 palms BSA involvement and severe psoriasis = >10 palms BSA involvement
bBased on the international (US/Canada/UK/EU/Japan) UPLIFT survey of 3200 patients currently experiencing psoriasis symptoms, conducted from March 2020 to June 2020
cBased on 3614 patients and 473 dermatologists in the UPLIFT survey
PsO, psoriasis; QoL, quality of life.
Gupta S et al. Dermatol Ther (Heidelb). 2021;11:2057-2075. Segaert S et al. J Dermatolog Treat. 2022;33:111-120. Lebwohl M et al. Dermatol Ther (Heidelb). 2022;12:61–78. Magee C et al. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.
While topical therapies are most commonly prescribed, are generally less costly, and have a good safety profile, patient reports indicate that some topicals may be inconvenient (eg, time-consuming and difficult to apply efficiently) and may not work for everyone.1-4,7,8 Patients are more satisfied with the efficacy of biologics but may find their treatment burdensome because of inconvenience or fear of injections.9-11 Orals provide convenience of administration that appeals to many patients, but patients may find their treatment burdensome because of adverse events and the need for laboratory monitoring.9-11 No matter the therapy chosen, there is an unmet need for improved management and patient education, and additional therapeutic options for patients with PsO, given that they continue to experience both symptoms that impact activities of daily living and QoL and significant burdens associated with treatment.5,9,10,12
Understanding patients’ needs and the impact on physical, psychological, and social well-being plays an important part in the overall management of psoriasis patients.13 Strategies to help achieve this include positive patient relationships, patient education, follow-up visits or calls, and patient participation in treatment decisions.8 Technology, such as apps supporting short-term adherence of patients with PsO to topical treatment, can also be used to engage with patients.8 Dermatologists are in key positions to directly influence patients’ perceptions of PsO and should establish clear long-term treatment goals to help manage patient expectations and experience, which remains a challenge in long-term management of PsO.8,13
Surveys suggest there are unmet needs in psoriasis
aModerate psoriasis = 4-10 palms BSA involvement and severe psoriasis = >10 palms BSA involvement
bBased on the international (US/Canada/UK/EU/Japan) UPLIFT survey of 3200 patients currently experiencing psoriasis symptoms, conducted from March 2020 to June 2020
cBased on 3614 patients and 473 dermatologists in the UPLIFT survey
PsO, psoriasis; QoL, quality of life.
Gupta S et al. Dermatol Ther (Heidelb). 2021;11:2057-2075. Segaert S et al. J Dermatolog Treat. 2022;33:111-120. Lebwohl M et al. Dermatol Ther (Heidelb). 2022;12:61–78. Magee C et al. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.
Surveys suggest there are unmet
needs in psoriasis
aModerate psoriasis = 4-10 palms BSA involvement and severe psoriasis = >10 palms BSA involvement
bBased on the international (US/Canada/UK/EU/Japan) UPLIFT survey of 3200 patients currently experiencing psoriasis symptoms, conducted from March 2020 to June 2020
cBased on 3614 patients and 473 dermatologists in the UPLIFT survey
PsO, psoriasis; QoL, quality of life.
Gupta S et al. Dermatol Ther (Heidelb). 2021;11:2057-2075. Segaert S et al. J Dermatolog Treat. 2022;33:111-120. Lebwohl M et al. Dermatol Ther (Heidelb). 2022;12:61–78. Magee C et al. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.
Despite the QoL burden associated with PsO, many patients remain untreated.1,2 Based on patient-reported treatment patterns from an international survey, 56% of patients who described extensive disease with psoriasis lesions involving body surface area corresponding to more than 10 palms reported being treated with an oral and/or biologic systemic therapy, while 58% of patients with involvement corresponding to 4-10 palms reported being treated with an oral and/or biologic.2 Furthermore, 12% of the patients who reported >10 palms BSA involvement and 16% who reported 4-10 palms BSA involvement reported receiving no prescription or phototherapy treatment at all, highlighting unmet needs in the management of PsO.2
Patients have reported dissatisfaction in multiple areas, including safety, ease of use, efficacy, and burden of treatment.2–4 A challenge for dermatologists is identifying which drug to prescribe for each patient, a decision that may commonly be based on the patient’s preference and medical history.1,5 However, this can result in patients cycling through several therapies before landing on one that works best for them.1,6 This extended period of cycling through different options may contribute to disease progression and poor outcomes.6
Surveys suggest there are unmet
needs in psoriasis
aModerate psoriasis = 4-10 palms BSA involvement and severe psoriasis = >10 palms BSA involvement
bBased on the international (US/Canada/UK/EU/Japan) UPLIFT survey of 3200 patients currently experiencing psoriasis symptoms, conducted from March 2020 to June 2020
cBased on 3614 patients and 473 dermatologists in the UPLIFT survey
PsO, psoriasis; QoL, quality of life.
Gupta S et al. Dermatol Ther (Heidelb). 2021;11:2057-2075. Segaert S et al. J Dermatolog Treat. 2022;33:111-120. Lebwohl M et al. Dermatol Ther (Heidelb). 2022;12:61–78. Magee C et al. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.
While topical therapies are most commonly prescribed, are generally less costly, and have a good safety profile, patient reports indicate that some topicals may be inconvenient (eg, time-consuming and difficult to apply efficiently) and may not work for everyone.1-4,7,8 Patients are more satisfied with the efficacy of biologics but may find their treatment burdensome because of inconvenience or fear of injections.9-11 Orals provide convenience of administration that appeals to many patients, but patients may find their treatment burdensome because of adverse events and the need for laboratory monitoring.9-11 No matter the therapy chosen, there is an unmet need for improved management and patient education, and additional therapeutic options for patients with PsO, given that they continue to experience both symptoms that impact activities of daily living and QoL and significant burdens associated with treatment.5,9,10,12
Surveys suggest there are unmet
needs in psoriasis
aModerate psoriasis = 4-10 palms BSA involvement and severe psoriasis = >10 palms BSA involvement
bBased on the international (US/Canada/UK/EU/Japan) UPLIFT survey of 3200 patients currently experiencing psoriasis symptoms, conducted from March 2020 to June 2020
cBased on 3614 patients and 473 dermatologists in the UPLIFT survey
PsO, psoriasis; QoL, quality of life.
Gupta S et al. Dermatol Ther (Heidelb). 2021;11:2057-2075. Segaert S et al. J Dermatolog Treat. 2022;33:111-120. Lebwohl M et al. Dermatol Ther (Heidelb). 2022;12:61–78. Magee C et al. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.
Understanding patients’ needs and the impact on physical, psychological, and social well-being plays an important part in the overall management of psoriasis patients.13 Strategies to help achieve this include positive patient relationships, patient education, follow-up visits or calls, and patient participation in treatment decisions.8 Technology, such as apps supporting short-term adherence of patients with PsO to topical treatment, can also be used to engage with patients.8 Dermatologists are in key positions to directly influence patients’ perceptions of PsO and should establish clear long-term treatment goals to help manage patient expectations and experience, which remains a challenge in long-term management of PsO.8,13
References
- Armstrong AW et al. Dermatol Ther (Heidelb). 2017;7:97–109.
- Lebwohl M et al. Dermatol Ther (Heidelb). 2022;12:61–78.
- Finch T et al. J Clin Aesthet Dermatol. 2015;8:26–30.
- Callis Duffin K et al. Br J Dermatol. 2014;170:672–680.
- Elmets CA et al. J Am Acad Dermatol. 2019;80:1073–1113.
- Magee C et al. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.
- Aldredge LM, Young MS. J Dermatol Nurses Assoc. 2016;8:14–26.
- Segaert S et al. J Dermatolog Treat. 2022;33:111–120.
- Lebwohl MG et al. J Am Acad Dermatol. 2014;70:871–881.e30.
- Lebwohl MG et al. Am J Clin Dermatol. 2016;17:87–97.
- Alcusky M et al. Dermatol Ther (Heidelb). 2017;7:463–483.
- Lacour JP et al. Dermatol Ther (Heidelb). 2020;10:1099–1109.
- Gupta S et al. Dermatol Ther (Heidelb). 2021;11:2057–2075.